188 related articles for article (PubMed ID: 9540852)
1. Proteoglycan breakdown from bovine nasal cartilage is increased, and from articular cartilage is decreased, by extracellular ATP.
Brown CJ; Caswell AM; Rahman S; Russell RG; Buttle DJ
Biochim Biophys Acta; 1997 Dec; 1362(2-3):208-20. PubMed ID: 9540852
[TBL] [Abstract][Full Text] [Related]
2. Cytokine-induced cartilage proteoglycan degradation is mediated by aggrecanase.
Arner EC; Hughes CE; Decicco CP; Caterson B; Tortorella MD
Osteoarthritis Cartilage; 1998 May; 6(3):214-28. PubMed ID: 9682788
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of cartilage proteoglycan release by a specific inactivator of cathepsin B and an inhibitor of matrix metalloproteinases. Evidence for two converging pathways of chondrocyte-mediated proteoglycan degradation.
Buttle DJ; Handley CJ; Ilic MZ; Saklatvala J; Murata M; Barrett AJ
Arthritis Rheum; 1993 Dec; 36(12):1709-17. PubMed ID: 8250991
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the degradation of type II collagen and proteoglycan in nasal and articular cartilages induced by interleukin-1 and the selective inhibition of type II collagen cleavage by collagenase.
Billinghurst RC; Wu W; Ionescu M; Reiner A; Dahlberg L; Chen J; van Wart H; Poole AR
Arthritis Rheum; 2000 Mar; 43(3):664-72. PubMed ID: 10728761
[TBL] [Abstract][Full Text] [Related]
5. Effects of growth factors and interleukin-1 alpha on proteoglycan and type II collagen turnover in bovine nasal and articular chondrocyte pellet cultures.
Xu C; Oyajobi BO; Frazer A; Kozaci LD; Russell RG; Hollander AP
Endocrinology; 1996 Aug; 137(8):3557-65. PubMed ID: 8754787
[TBL] [Abstract][Full Text] [Related]
6. Resistance of small leucine-rich repeat proteoglycans to proteolytic degradation during interleukin-1-stimulated cartilage catabolism.
Sztrolovics R; White RJ; Poole AR; Mort JS; Roughley PJ
Biochem J; 1999 May; 339 ( Pt 3)(Pt 3):571-7. PubMed ID: 10215595
[TBL] [Abstract][Full Text] [Related]
7. N-terminal sequence of proteoglycan fragments isolated from medium of interleukin-1-treated articular-cartilage cultures. Putative site(s) of enzymic cleavage.
Loulakis P; Shrikhande A; Davis G; Maniglia CA
Biochem J; 1992 Jun; 284 ( Pt 2)(Pt 2):589-93. PubMed ID: 1599440
[TBL] [Abstract][Full Text] [Related]
8. Stimulation of cartilage resorption by extracellular ATP acting at P2-purinoceptors.
Leong WS; Russell RG; Caswell AM
Biochim Biophys Acta; 1994 Nov; 1201(2):298-304. PubMed ID: 7947945
[TBL] [Abstract][Full Text] [Related]
9. The mechanism of aggrecan release from cartilage differs with tissue origin and the agent used to stimulate catabolism.
Sztrolovics R; White RJ; Roughley PJ; Mort JS
Biochem J; 2002 Mar; 362(Pt 2):465-72. PubMed ID: 11853556
[TBL] [Abstract][Full Text] [Related]
10. Aggrecanase versus matrix metalloproteinases in the catabolism of the interglobular domain of aggrecan in vitro.
Little CB; Flannery CR; Hughes CE; Mort JS; Roughley PJ; Dent C; Caterson B
Biochem J; 1999 Nov; 344 Pt 1(Pt 1):61-8. PubMed ID: 10548534
[TBL] [Abstract][Full Text] [Related]
11. "Aggrecanase" activity is implicated in tumour necrosis factor alpha mediated cartilage aggrecan breakdown but is not detected by an in vitro assay.
Buttle DJ; Fowles A; Ilic MZ; Handley CJ
Mol Pathol; 1997 Jun; 50(3):153-9. PubMed ID: 9292151
[TBL] [Abstract][Full Text] [Related]
12. TIMP-3 inhibits aggrecanase-mediated glycosaminoglycan release from cartilage explants stimulated by catabolic factors.
Gendron C; Kashiwagi M; Hughes C; Caterson B; Nagase H
FEBS Lett; 2003 Dec; 555(3):431-6. PubMed ID: 14675751
[TBL] [Abstract][Full Text] [Related]
13. Nitric oxide inhibits aggrecan degradation in explant cultures of equine articular cartilage.
Bird JL; May S; Bayliss MT
Equine Vet J; 2000 Mar; 32(2):133-9. PubMed ID: 10743969
[TBL] [Abstract][Full Text] [Related]
14. Passive loss of proteoglycan from articular cartilage explants.
Bolis S; Handley CJ; Comper WD
Biochim Biophys Acta; 1989 Dec; 993(2-3):157-67. PubMed ID: 2512986
[TBL] [Abstract][Full Text] [Related]
15. Release of hyaluronan and hyaladherins (aggrecan G1 domain and link proteins) from articular cartilage exposed to ADAMTS-4 (aggrecanase 1) or ADAMTS-5 (aggrecanase 2).
Chockalingam PS; Zeng W; Morris EA; Flannery CR
Arthritis Rheum; 2004 Sep; 50(9):2839-48. PubMed ID: 15457452
[TBL] [Abstract][Full Text] [Related]
16. Evidence that the inhibition of cartilage proteoglycan breakdown by mannosamine is not mediated via inhibition of glycosylphosphatidylinositol anchor formation.
Bryson H; Buttle DJ; Kozaci LD; Johnatty RN; Bunning RA
Biochem J; 2000 Feb; 345 Pt 3(Pt 3):495-501. PubMed ID: 10642507
[TBL] [Abstract][Full Text] [Related]
17. Monoclonal antibodies that specifically recognize neoepitope sequences generated by 'aggrecanase' and matrix metalloproteinase cleavage of aggrecan: application to catabolism in situ and in vitro.
Hughes CE; Caterson B; Fosang AJ; Roughley PJ; Mort JS
Biochem J; 1995 Feb; 305 ( Pt 3)(Pt 3):799-804. PubMed ID: 7531436
[TBL] [Abstract][Full Text] [Related]
18. IL-6 and its soluble receptor augment aggrecanase-mediated proteoglycan catabolism in articular cartilage.
Flannery CR; Little CB; Hughes CE; Curtis CL; Caterson B; Jones SA
Matrix Biol; 2000 Nov; 19(6):549-53. PubMed ID: 11068209
[TBL] [Abstract][Full Text] [Related]
19. A serine proteinase inactivator inhibits chondrocyte-mediated cartilage proteoglycan breakdown occurring in response to proinflammatory cytokines.
Bryson H; Bunning RA; Feltell R; Kam CM; Kerrigan J; Powers JC; Buttle DJ
Arch Biochem Biophys; 1998 Jul; 355(1):15-25. PubMed ID: 9647662
[TBL] [Abstract][Full Text] [Related]
20. Inhibitors of hyaluronan export prevent proteoglycan loss from osteoarthritic cartilage.
Prehm P
J Rheumatol; 2005 Apr; 32(4):690-6. PubMed ID: 15801027
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
